Drug therapy for chronic idiopathic axonal polyneuropathy

Cochrane Database of Systematic Reviews

Volumn 2004, Issue 2, 2004, Pages

  Vrancken, Alexander F J E ^a   van Schaik, Ivo N ^b   Hughes, Richard A C ^c   Notermans, Nicolette C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ATAXIA; CHRONIC DISEASE; HUMAN; INNERVATION; LEG; NERVE FIBER; POLYNEUROPATHY; REVIEW;

AGED; AXONS; CHRONIC DISEASE; GAIT ATAXIA; HUMANS; LEG; POLYNEUROPATHIES;

EID: 84921704230     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003456.pub2     Document Type: Review

References (116)

1. Bradley WG, Badger GJ, Tandan R, Fillyaw MJ, Young J, Fries TJ, et al.Double-blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxia. Neurology 1988;38(11):1731-9. [PUBMED: 2847079].
2. De Grandis D, Santoro L, Di Benedetto P. L-acetylcarnitine in the treatment of patients with peripheral neuropathies: A short term, double-blind clinical study of 426 patients. Clinical Drug Investigation 1995;10(6):317-22. [EMBASE: 1996006029].
3. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008;336(7637):199-201. [PUBMED: 18182416].
4. Galer BS, Twilling LL, Harle J, Cluff RS, Friedman E, Rowbotham MC. Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions. Neurology 2000;55(7):971-5. [PUBMED: 11061253].
5. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. The Clinical Journal of Pain 2008;24(1):51-5. [PUBMED: 18180637].
6. Ho TW, Backonja M, Ma J, Leibensperger H, Froman S, Polydefkis M. Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain 2009;141(1-2):19-24. [PUBMED: 19013718].
7. Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, et al.Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. European Journal of Pain 2010;14(4):387-94. [PUBMED: 19733106].
8. Husstedt IW, Thümler R, Röder R, Dreyer M, Leopold W, Scheller W. Behandlung von Polyneuropathien. Untersuchungen zur Wirksamkeit von Ginkgo-biloba-Exrakt EGb 761 bei Patienten mit Polyneuropathie. Zeitschrift für Allgemeine Medizin 1993;69:714-7. [EMBASE: 1993302831].
9. Kishore-Kumar R, Schafer SC, Lawlor BA, Murphy DL, Max MB. Single doses of the serotonin agonists buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain. Pain 1989;37(2):223-7. [PUBMED: 2664664].
10. Langohr HD, Stohr M, Petruch F. An open and double-blind cross-over study on the efficacy of clomipramine (Anafranil) in patients with painful mono- and polyneuropathies. European Neurology 1982;21(5):309-17. [PUBMED: 6126361].
11. Li L. The effect of Neuragen PN on neuropathic pain: a randomized, double blind, placebo controlled clinical trial. BMC Complementary and Alternative Medicine 2010;10:22. [PUBMED: 20487567].
12. Low PA, Opfer-Gehrking TL, Dyck PJ, Litchy WJ, O'Brien PC. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 1995;62(2):163-8. [PUBMED: 8545141].
13. Maier C, Hildebrandt J, Klinger R, Henrich-Ebert C, Lindena G, the MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic no-tumor associated pain - results of a double-blind placebo-controlled trial (MONTAS). Pain 2002;97:223-33. [PUBMED: 12044619].
14. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, et al.Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8. [PUBMED: 14581122].
15. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliative Medicine 2003;17:576-87. [PUBMED: 14594148].
16. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133(1-3):210-20. [PUBMED: 17997224].
17. Onofrj M, Fulgente T, Melchionda D, Marchionni A, Tomasello F, Salpietro FM, et al.L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. International Journal of Clinical Pharmacology Research 1995;15(1):9-15. [PUBMED: 7490173].
18. Otto M, Bach FW, Jensen TS, Sindrup SH. Valproic acid has no effect in polyneuropathy. A randomized, controlled trial. Neurology 2004;62(2):285-8. [PUBMED: 14745070].
19. Otto M, Bach FW, Jensen TS, Brøsen K, Sindrup SH. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain 2008;139(2):275-83. [PUBMED: 18547727].
20. Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, et al. The Ziconotide Study Group. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. Journal of Pain and Symptom Management 2006;31(5):393-406. [PUBMED: 16716870].
21. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine 2003;348(13):1223-32. [PUBMED: 12660386].
22. Semenchuck MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001;57(9):1583-8. [PUBMED: 11706096].
23. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999;83(1):85-90. [PUBMED: 10506675].
24. Sindrup SH, Madsen C, Brosen K, Jensen TS. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clinical Pharmacology and Therapeutics 1999;66(6):636-41. [PUBMED: 10613620].
25. Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS. St. John's wort has no effect on pain in polyneuropathy. Pain 2001;91(3):361-5. [PUBMED: 11275394].
26. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy. Neurology 2003;60(8):1284-9. [PUBMED: 12707430].
27. Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindstrom T, Thorell. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clinical Journal of Pain 1997;13(4):313-23. [PUBMED: 9430812].
28. Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study. Regional Anesthesia and Pain Medicine 2000;25(5):459-67. [PUBMED: 11009230].
29. Wallace MS, Rowbotham M, Bennett GJ, Jensen TS, Pladna R, Quessy S. A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. Journal of Pain 2002;3(3):227-33. [PUBMED: 14622777].
30. Windebank AJ, Sorenson EJ, Civil R, O'Brien PC. Role of insulin-like growth factor-I in the treatment of painful small fiber predominant neuropathy. Journal of the Peripheral Nervous System 2004;9:183-9. [PUBMED: 15363067].
31. Ang CD, Alviar MJ, Dans AL, Bautista-Velez GG, Villaruz-Sulit MV, Tan JJ, et al.Vitamin B for treating peripheral neuropathy. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD004573.pub3; PUBMED: 18646107].
32. Argov Z, Steiner I, Soffer D. The yield of sural nerve biopsy in the evaluation of peripheral neuropathies. Acta Neurologica Scandinavica 1989;79:243-5.
33. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al.EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010;17(9):1113-e88. [PUBMED: 20402746].
34. Bosboom WM, Van den Berg LH, Dieks HJ, Plante E, Veldman H, Franssen H, et al.Unmyelinated nerve fiber degeneration in chronic inflammatory demyelinating polyneuropathy. Acta Neuropathologica (Berlin) 2000;99:571-8.
35. Camerlingo M, Nemni R, Ferraro B, Casto L, Partziguian T, Censori B, et al.Malignancy and sensory neuropathy of unexplained cause: a prospective study of 51 patients. Archives of Neurology 1998;55:981-4.
36. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44(11):1973-88.
37. Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. Journal of Pain 2006;7(2):119-28.
38. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003345.pub2].
39. Chia L, Fernandez A, Lacroix C, Plante V, Said G. Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly. A retrospective review of 100 consecutive patients. Brain 1996;119:1091-8.
40. Deprez M, De Groote CC, Gollogly L, Reznik M, Martin JJ. Clinical and neuropathological parameters affecting the diagnostic yield of nerve biopsy. Neuromuscular Disorders 2000;10:92-8.
41. Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007393.pub2; PUBMED: 19821411].
42. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
43. Dray A. Neuropathic pain: emerging treatments. British Journal of Anaesthesia 2008;101(1):48-58.
44. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpàa ML, et al.Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinic Proceedings 2010;85(3 Suppl):S3-14. [PUBMED: 20194146].
45. Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Annals of Neurology 1981;10:222-6.
46. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton III LJ, O'Brien PC, et al.The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41:799-807.
47. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton III LJ. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42:1164-70.
48. Dyck PJ, Dyck PJ, Klein CJ, Weigand SD. Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle & Nerve 2007;36(4):536-41. [PUBMED: 17626290].
49. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006146; PUBMED: 16856116].
50. Eliasson B. Cigarette smoking and diabetes. Progression in Cardiovascular Disease 2003;45(5):405-13.
51. Erdmann PG, van Genderen FR, Teunissen LL, Notermans NC, Lindeman E, van Wijck AJ, et al.Pain in patients with chronic idiopathic axonal polyneuropathy. European Neurology 2010;64(1):58-64. [PUBMED: 20634621].
52. Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. Medscape General Medicine 2007;9(2):36. [PUBMED: 17955091].
53. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997;46(4):665-70.
54. Fressinaud C, Jean I, Dubas F. Selective decrease in axonal nerve growth factor and insulin-like growth factor I immunoreactivity in axonopathies of unknown etiology. Acta Neuropathologica (Berlin) 2003;105(5):477-83.
55. Gabriel CM, Howard R, Kinsella N, Lucas S, McColl I, Saldanha G, et al.Prospective study of the usefulness of sural nerve biopsy. Journal of Neurology, Neurosurgery, and Psychiatry 2000;69:442-6.
56. Gold BG. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opinion on Investigational Drugs 2000;9(10):2331-42.
57. Gold BG, Udina E, Bourdette D, Navarro X. Neurorgenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies. Neurologic Research 2004;26(4):371-80.
58. Graham RC, Hughes RAC. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(8):973-6.
59. Graham RC, Hughes RAC. Clinimetric properties of a walking scale in peripheral neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(8):977-9.
60. Grahmann F, Winterholler M, Neundörfer B. Cryptogenetic polyneuropathies: an out-patient follow-up study. Acta Neurologica Scandinavica 1991;84:221-5.
61. Herman RM, Brower JB, Stoddard DG, Casano AR, Targovnik JH, Herman JH, et al.Prevalence of somatic small fiber neuropathy in obesity. International Journal of Obesity 2007;31(2):226-35.
62. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
63. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
64. Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD003726.pub3].
65. Hughes RAC, Umapathi T, Gray IA, Gregson NA, Noori M, Pannala AS, Proteggente A, Swan AV. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004;127(Pt 8):1723-30.
66. Jann S, Gatti A, Crespi S, Rolo J, Beretta S. Peripheral neuropathy in chronic respiratory insufficiency. Journal of the Peripheral Nervous System 1998;3(1):69-74.
67. Jann S, Beretta S, Bramerio M, Defanti CA. Prospective follow-up study of chronic polyneuropathy of undetermined cause. Muscle & Nerve 2001;24(9):1197-201.
68. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle & Nerve 1991;14:1103-9.
69. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. Journal of the Peripheral Nervous System 2004;9:26-53.
70. Li Y, Fang D, Tian H, Wu T. Prostaglandin E1 for diabetic neuropathy. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD006051].
71. Lindh J, Tondel M, Österberg A, Vrethem M. Cryptogenic polyneuropathy: clinical and neurophysiological findings. Journal of the Peripheral Nervous System 2005;10:31-7.
72. Logigian EL, Kelly JJ, Jr, Adelman LS. Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle & Nerve 1994;17:1010-20.
73. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2; PUBMED: 19821395].
74. Malik RA. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?. Annals of Medicine 2000;32(1):1-5.
75. Markman JD, Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. Journal of Pain 2006;7(15 Supplement 1):S38-S47.
76. McLeod JG, Tuck RR, Pollard JD, Cameron J, Walsh JC. Chronic polyneuropathy of undetermined cause. Journal of Neurology, Neurosurgery, and Psychiatry 1984;47:530-5. [MEDLINE: 84241840].
77. Merkies ISJ, Lauria G. 131st ENMC International workshop: Selection of outcome measures for peripheral neuropathy clinical trials, 10-12 December, Naarden, The Netherlands. Neuromuscular Disorders 2006;16:149-56.
78. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001447.pub2].
79. Mirza N, Cornblath DR, Hassan S, Hussain U. Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005492].
80. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2; PUBMED: 19588419].
81. Müller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nature Reviews Drug Discovery 2005;4(5):387-98.
82. Nebuchennykh M, Loseth S, Jorde R, Mellgren SI. Idiopathic polyneuropathy and impaired glucose metabolism in a Norwegian patient series. European Journal of Neurology 2008;15(8):810-6. [PUBMED: 18549398].
83. Neundörfer B, Grahmann F, Engelhardt A, Harte U. Postoperative effects and value of sural nerve biopsies: a retrospective study. European Neurology 1990;30:350-2.
84. Notermans NC, Wokke JHJ, Franssen H, Van der Graaf Y, Vermeulen M, Van den Berg LH, et al.Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. Journal of Neurology, Neurosurgery, and Psychiatry 1993;56:1066-71.
85. Notermans NC, Wokke JHJ, Van der Graaf Y, Franssen H, van Dijk GW, Jennekens FG. Chronic idiopathic axonal polyneuropathy: a five year follow up. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57:1525-7.
86. Oh SJ. Diagnostic usefulness and limitations of the sural nerve biopsy. Yonsei Medical Journal 1990;31:1-26. [MEDLINE: 90266597].
87. Ossipov MH, Porreca F. Challenges in the development of novel treatment strategies for neuropathic pain. Journal of the American Society for Experimental NeuroTherapeutics 2005;2(4):650-61.
88. Poza JJ, Martí-Massó JF. Peripheral neuropathy associated with chronic obstructive pulmonary disease [Neuropatía periférica asociada a enfermedad pulmonar obstructiva crónica]. Neurología 1997;12(9):389-94.
89. Pradat PF. Treatment of peripheral neuropathies with neurotrophic factors: animal models and clinical trials [Traitement des neuropathies périphériques par les facteurs neurotrophiques: des models animaux et essais thérapeutiques]. Revue Neurologique 2003;159(2):147-61. [MEDLINE: 12660566].
90. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scottish Medical Journal 1957;2:200-15.
91. Rappaport WD, Valente J, Hunter GC, Rance NE, Lick S, Lewis T, et al.Clinical utilization and complications of sural nerve biopsy. American Journal of Surgery 1993;166:252-6.
92. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.02. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
93. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews 2007;Issue 4:CD005454. [PUBMED: 17943857].
94. Sackley C, Disler PB, Turner-Stokes L, Wade DT. Rehabilitation interventions for foot drop in neuromuscular disease. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD003908.pub3].
95. Sah DW, Ossipo MH, Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nature Reviews. Drug Discovery 2003;2(6):460-72. [MEDLINE: 12776221].
96. Saperstein DS, Wolfe GI, Gronseth GS, Nations SP, Herbelin LL, Bryan WW, Barohn RJ. Challenges in the identification of cobalamin-deficiency polyneuropathy. Archives of Neurology 2003;60(9):1296-1301.
97. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al.Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006;29(6):1294-9. [PUBMED: 16732011].
98. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. The Neurologist 2008;14(1):23-9. [PUBMED: 18195653].
99. Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. Journal of the Neurological Sciences 2008;273(1-2):25-8. [PUBMED: 18606421].
100. Teunissen LL, Eurelings M, Notermans NC, Hop JW, van Gijn J. Quality of life in patients with axonal polyneuropathy. Journal of Neurology 2000;247:195-9.
101. Teunissen LL, Notermans NC, Wokke JHJ. Relationship between ischemia and neuropathy. European Neurology 2000;44:1-7.
102. Teunissen LL, Notermans NC, Jansen GH, Banga JD, Veldman H, Wokke JHJ. Thickness of endoneurial vessel basal lamina area in chronic idiopathic axonal polyneuropathy. Acta Neuropathologica (Berlin) 2000;100:445-50.
103. Teunissen LL, Franssen H, Wokke JHJ, Van der Graaf Y, Linssen WHJP, Banga JD, et al.Is cardiovascular disease a risk factor in the development of axonal polyneuropathy?. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72:590-5.
104. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
105. Vilming ST, Stave R. Idiopathic polyneuropathy. A prospective study including gastrointestinal investigation. Journal of Oslo City Hospital 1987;37:129-34.
106. Vrancken AFJE, Franssen H, Wokke JHJ, Teunissen LL, Notermans NC. Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system in elderly people. Archives of Neurology 2002;59(4):533-40.
107. Vrancken AFJE, Notermans NC, Jansen GH, Wokke JHJ, Said G. Progressive idiopathic axonal neuropathy: a comparative clinical and histopathological study with vasculitic neuropathy. Journal of Neurology 2004;251:269-78.
108. White CM, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003904.pub2].
109. White CM, van Doorn PA, Garssen MPJ, Stockley RC. Interventions for fatigue in peripheral neuropathy. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008146].
110. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005452.pub2].
111. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005451].
112. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006044.pub2; PUBMED: 17443611].
113. Wolfe GI, Baker NS, Amato AA, Jackson CE, Nations SP, Saperstein DS, et al.Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Archives of Neurology 1999;56:540-7.
114. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008;31(3):464-9. [PUBMED: 18039804].
115. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come?. Diabetes care 2008;31 Suppl 2:S255-61. [PUBMED: 18227494].
116. Zochodne DW, Levy D. Nitric oxide in damage, disease and repair of the peripheral nervous system. Cellular & Molecular Biology 2005;51(3):255-67.